# Warner-Lambert v. Reynolds: The Listerine Royalty That Never Ends

> A 1959 court held Listerine's maker owed royalties on an 1881 secret-formula contract even after the formula went public, because the contract set duration.

Topic: Trade Secrets  |  Author: Lidiia Levitska  |  Source: Intellectual Property Law (outsideipcounsel.com)
Canonical: https://outsideipcounsel.com/blog/warner-lambert-v-reynolds-listerine-perpetual-royalty/


Few contracts run for well over a century, but the agreement at the heart of *Warner-Lambert Pharmaceutical Co. v. John J. Reynolds, Inc.*, 178 F. Supp. 655 (S.D.N.Y. 1959), aff'd, 280 F.2d 197 (2d Cir. 1960), did exactly that. The maker of Listerine sought a declaration that it no longer had to pay royalties under an 1881 contract for the mouthwash's secret formula, arguing that the formula had long since become public. The United States District Court for the Southern District of New York disagreed, holding that the obligation to pay was governed by the contract's terms, which tied royalties to the manufacture and sale of Listerine, not to the secrecy of the formula. The Second Circuit affirmed.

The case is the classic authority on the duration of trade-secret license royalties, and a durable drafting lesson: the life of a payment obligation is set by the contract, not by the life of the secret. A licensee who wants to stop paying when a formula goes public must negotiate that term at the outset, because courts will enforce the words the parties chose.

## At a glance

- **Case:** *Warner-Lambert Pharmaceutical Co. v. John J. Reynolds, Inc.*, 178 F. Supp. 655 (S.D.N.Y. 1959), aff'd, 280 F.2d 197 (2d Cir. 1960).
- **Decided:** 1959 in the district court, affirmed 1960 by the Second Circuit; judgment for the licensor.
- **Holding:** A trade-secret license's royalty obligation is co-extensive with the manufacture and sale of the product, as the contract provides, and does not terminate merely because the underlying formula has become public.
- **Status:** Final; a foundational and still-cited decision on trade-secret license duration.

## The doctrinal frame: contract governs, not the secret's lifespan

The instinctive analogy a licensee reaches for is patent and copyright law. A patent expires after a set term, and royalties tied to a patent generally cannot be collected past expiration. Surely, the argument runs, a trade-secret license should likewise end when the secret dies. *Warner-Lambert* rejects that analogy. Unlike patents and copyrights, which are creatures of statute with fixed terms, a trade-secret license is a private contract. Its duration and its conditions are whatever the parties agreed, subject to the ordinary rules of contract interpretation.

The court's method was straightforward and textual. It asked what the 1881 agreement actually said about when payments were due, and it found language tying the royalty to Lambert's, and his successors', manufacture and sale of Listerine. Nothing in the contract conditioned the payment on the formula remaining secret. Because the plain meaning controlled, the obligation continued for as long as Warner-Lambert kept making and selling the product, whatever the world had learned about the recipe in the interim.

## The facts and posture

In 1881, Dr. J.J. Lawrence licensed the formula for Listerine to Jordan Lambert. The contract provided that Lambert and his successors in interest would pay a specified royalty to Lawrence and his successors for so long as Lambert and his successors manufactured or sold Listerine. Over the following decades the business grew into a pharmaceutical giant, and the royalty stream flowed to Lawrence's successors, including the defendant John J. Reynolds, Inc., and other assignees.

The formula did not stay secret. By the mid-twentieth century it had been published in the United States Pharmacopeia, the National Formulary, and the Journal of the American Medical Association, and it had surfaced in Federal Trade Commission proceedings against the company's predecessor. Warner-Lambert, the successor manufacturer, sued for a declaratory judgment that because the formula was no longer a trade secret, it owed no further royalties. It argued, among other things, that trade-secret licenses should be treated like patent or copyright licenses and should terminate when the protected subject matter entered the public domain.

## The court's reasoning

The court held Warner-Lambert to its bargain. It reasoned that the contract's language was the measure of the obligation, and that language made the royalty co-extensive with the manufacture or sale of Listerine. Neither the passage of time nor the publication of the formula relieved the manufacturer of its duty, because the parties had not tied the payment to secrecy. Had they wished to make continued royalties contingent on the formula remaining confidential, they could have said so; they did not.

The court declined to import a patent-style expiration rule into a private trade-secret contract. Patents and copyrights carry statutory terms because Congress created them with fixed durations to balance incentive and public access. A trade-secret license carries no such built-in expiration. It is a matter of agreement, and courts enforce the agreement as written. The result was that Warner-Lambert continued to owe royalties on a formula anyone could look up, because it had promised to pay for as long as it sold the product, and it kept selling the product.

## What it changed

*Warner-Lambert* is cited to this day for the proposition that the subject matter of a trade-secret license does not determine the duration of the license. The teaching is aimed squarely at drafters. A licensee that accepts an obligation to pay "for as long as the product is sold" has agreed to a potentially perpetual royalty, and it cannot later escape by pointing to the loss of secrecy. Conversely, a licensor who wants payments to continue past public disclosure should tie the obligation to sales rather than to secrecy, exactly as the Listerine contract did.

The decision also frames a strategic choice at the negotiating table. Licensees routinely seek clauses providing that royalties abate or terminate if the licensed information becomes publicly available, whether through the licensor's fault, third-party disclosure, or independent development. Licensors resist such clauses to preserve a durable revenue stream. *Warner-Lambert* is the reason that clause exists and the reason its presence or absence can be worth a fortune.

## Open questions

The opinion leaves room at the margins. It does not decide how a court should treat a contract that is ambiguous about whether royalties depend on secrecy, where interpretation might cut the other way. It does not address the modern federal-preemption argument that enforcing a perpetual royalty on public information conflicts with the policy that unpatented, publicly known matter is free for all to use, a tension the Supreme Court later engaged in the patent-royalty context. And it does not resolve how the rule interacts with unconscionability or changed-circumstances doctrines when a royalty stream continues for an extraordinarily long time. The core holding, however, remains intact: the contract's words, not the secret's survival, govern.

## Implications for creators and businesses

- **Tie duration to the right trigger.** If royalties should stop when secrecy ends, say so expressly. If they should continue with sales, use sales-based language as the Listerine contract did.
- **Licensees should negotiate a public-domain off-ramp.** A clause abating or terminating royalties if the information becomes publicly available prevents the open-ended liability Warner-Lambert faced.
- **Do not rely on patent analogies.** Trade-secret licenses have no built-in expiration. Courts will not read a statutory-style term into a private contract that lacks one.
- **Read the survival and termination clauses first.** In any technology license, the duration provisions can outweigh the substantive grant. The Listerine contract bound its maker for over a century on those words alone.

## Frequently asked questions

**Why did Warner-Lambert have to keep paying royalties after the Listerine formula became public?** Because the 1881 contract tied the payment obligation to the manufacture and sale of Listerine, not to the continued secrecy of the formula. The court read the plain language as making royalties co-extensive with sales, so publication of the formula did not end the duty to pay.

**Does a trade-secret license automatically terminate when the secret becomes public?** No. *Warner-Lambert* holds that a trade-secret license's duration is governed by the contract's terms, not by the life of the secret. If the parties want payments to stop when secrecy ends, they must say so; absent that language, the obligation can be perpetual.

**How can drafters avoid a perpetual royalty like Listerine's?** Tie the payment obligation expressly to continued secrecy or set a fixed term. A clause providing that royalties cease if and when the licensed information enters the public domain, or after a defined number of years, prevents the open-ended liability the Listerine contract created.

## Authorities and sources

- *Warner-Lambert Pharmaceutical Co. v. John J. Reynolds, Inc.*, 178 F. Supp. 655 (S.D.N.Y. 1959) (Bryan, J.), full opinion (Caselaw Access Project): https://static.case.law/f-supp/178/html/0655-01.html
- *Warner-Lambert Pharmaceutical Co. v. John J. Reynolds, Inc.*, 280 F.2d 197 (2d Cir. 1960) (per curiam), full opinion (Caselaw Access Project): https://static.case.law/f2d/280/html/0197-01.html
- Archer & Greiner, "Bad Contracting Can Leave a Bad Taste in Your Mouth": https://www.archerlaw.com/bad-contracting-can-leave-a-bad-taste-in-your-mouth/
- Casebriefs, "Warner-Lambert Pharmaceutical Co. v. John J. Reynolds, Inc.": https://www.casebriefs.com/blog/law/intellectual-property-law/intellectual-property-keyed-to-merges/trade-secret-protection/warner-lambert-pharmaceutical-co-v-john-j-reynolds-inc/